Terms: = Head and neck cancer AND HOXD13, SPD, 3239, P35453, HOX4I AND Prognosis
10 results:
1. Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor prognosis in Esophageal Squamous Cell Carcinoma.
Shiraishi T; Toyozumi T; Sakata H; Murakami K; Kano M; Matsumoto Y; Yokoyama M; Okada K; Kamata T; Ryuzaki T; Kinoshita K; Hirasawa S; Matsubara H
Oncology; 2022; 100(1):39-47. PubMed ID: 34991094
[TBL] [Abstract] [Full Text] [Related]
2. The clinical implication of soluble PD-L1 (spd-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte.
Han B; Dong L; Zhou J; Yang Y; Guo J; Xuan Q; Gao K; Xu Z; Lei W; Wang J; Zhang Q
Cancer Immunol Immunother; 2021 Oct; 70(10):2893-2909. PubMed ID: 33688997
[TBL] [Abstract] [Full Text] [Related]
3. PD-L1, PDK-1 and p-Akt are correlated in patients with papillary thyroid carcinoma.
Wang H; Zhang Z; Yan Z; Ma S
Adv Clin Exp Med; 2020 Jul; 29(7):785-792. PubMed ID: 32750756
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
Singh L; Singh MK; Rizvi MA; Pushker N; Bakhshi S; Sen S; Kashyap S
Br J Ophthalmol; 2021 Jan; 105(1):48-56. PubMed ID: 32277010
[TBL] [Abstract] [Full Text] [Related]
5. Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer.
Yoshida J; Ishikawa T; Doi T; Ota T; Yasuda T; Okayama T; Sakamoto N; Inoue K; Dohi O; Yoshida N; Kamada K; Uchiyama K; Takagi T; Konishi H; Naito Y; Itoh Y
Med Oncol; 2019 May; 36(7):60. PubMed ID: 31134385
[TBL] [Abstract] [Full Text] [Related]
6. HOXB9 Expression Correlates with Histological Grade and prognosis in LSCC.
Sun C; Han C; Wang P; Jin Y; Sun Y; Qu L
Biomed Res Int; 2017; 2017():3680305. PubMed ID: 28808656
[TBL] [Abstract] [Full Text] [Related]
7. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
Nagato T; Ohkuri T; Ohara K; Hirata Y; Kishibe K; Komabayashi Y; Ueda S; Takahara M; Kumai T; Ishibashi K; Kosaka A; Aoki N; Oikawa K; Uno Y; Akiyama N; Sado M; Takei H; Celis E; Harabuchi Y; Kobayashi H
Cancer Immunol Immunother; 2017 Jul; 66(7):877-890. PubMed ID: 28349165
[TBL] [Abstract] [Full Text] [Related]
8. Findings of computed tomography in stage IIB and IIC melanoma: a six-year retrospective study in the South-East of Scotland.
Orfaniotis G; Mennie JC; Fairbairn N; Butterworth M
J Plast Reconstr Aesthet Surg; 2012 Sep; 65(9):1216-9. PubMed ID: 22525255
[TBL] [Abstract] [Full Text] [Related]
9. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer.
Esteva D; Muros MA; Llamas-Elvira JM; Jiménez Alonso J; Villar JM; López de la Torre M; Muros T
Ann Surg Oncol; 2009 Jul; 16(7):2006-13. PubMed ID: 19415387
[TBL] [Abstract] [Full Text] [Related]
10. [Study on the correlation between the expression of protein p53 at stage III nasopharyngeal carcinoma and its biological behavior, prognosis, p53 gene mutation and the expression of LMP-1].
Xu S; Zhang W
Zhonghua Bing Li Xue Za Zhi; 2001 Dec; 30(6):456-9. PubMed ID: 11866991
[TBL] [Abstract] [Full Text] [Related]
